AzTrials
AzTrials

LLIN, PBO LLIN, IRS, LarvicidingNCT04182126

Adaptive Interventions for Optimizing Malaria Control: a Cluster-Randomized SMART Trial

A study testing Regular long-lasting insecticidal nets, LLIN plus Piperonyl butoxide-treated LLIN and Long-lasting microbial larvicide in people with LLIN, PBO LLIN, IRS, Larviciding, run by University of California, Irvine at 2 sites in 2 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

In the past decade, massive scale-up of long-lasting insecticidal nets (LLINs) and indoor residual spraying (IRS) have led to significant reductions in malaria mortality and morbidity. Read more about this study

Who is it for?
Ages 6 months and olderHealthy volunteers can take part
Conditions the study is for
LLIN, PBO LLIN, IRS, Larviciding
What is being tested?
Regular long-lasting insecticidal nets, LLIN plus Piperonyl butoxide-treated LLIN and Long-lasting microbial larvicide
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
122,872 participants
Where
2 sitesin 2 countries
Study dates
1 Dec 2019to 31 Aug 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 months and older
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Household inclusion criteria:

  • Households with residents at the time of survey
  • Agreement of the adult resident to provide informed consent for the intervention and survey

Study subjects inclusion criteria:

  • Passive case detection by health facilities will include all residents in the study clusters; active case detection will include residents of >6 months
  • Agreement of parent/guardian to provide informed consent and minors to provide assent.

Household exclusion criteria:

  • Household vacant
  • No adult resident home on more than 3 occasions

Study subjects exclusion criteria:

  • Participants not home on day of survey

Trial locations and contacts

2 sites in 2 countries.

2 sites in 2 countries

United States1 site
  • Program in Public Health

    Irvine, California, 92697

Other trials in United States

Kenya1 site
  • Tom-Mboya University College, Maseno University

    Homa Bay, Homa Bay County

Other trials in Kenya

About this study

Official title: Environmental Modifications in Sub-Saharan Africa: Changing Epidemiology, Transmission and Pathogenesis of Plasmodium Falciparum and P. Vivax Malaria

In the past decade, massive scale-up of long-lasting insecticidal nets (LLINs) and indoor residual spraying (IRS) have led to significant reductions in malaria mortality and morbidity. Nonetheless, malaria burden remains high, and a dozen countries in Africa show a trend of increasing malaria incidence over the past several years. The high malaria burden in many areas of Africa underscores the need to improve the effectiveness of intervention tools by optimizing first-line intervention tools and integrating newly approved products into control programs. Vector control is an important component of the national malaria control strategy in Africa. Because transmission settings and vector ecology vary among countries or among districts within a country, interventions that work in one setting may not work well in all settings. Malaria interventions should be adapted and re-adapted over time in response to evolving malaria risks and changing vector ecology and behavior. The central objective of this application is to design optimal adaptive combinations of vector control interventions to maximize reductions in malaria burden based on local malaria transmission risks, changing vector ecology, and available mix of interventions approved by the Ministry of Health in each target country. The central hypothesis is that an adaptive approach based on local malaria risk and changing vector ecology will lead to significant reductions in malaria incidence and transmission risk. The aim of this study is to use a cluster-randomized sequential, multiple assignment randomized trial (SMART) design to compare various vector control methods implemented by the Ministry of Health of Kenya in reducing malaria incidence and infection, and develop an optimal intervention strategy tailored toward to local epidemiological and vector conditions.

Read the detailed description

In the past decade, massive scale-up of long-lasting insecticide-treated nets (LLINs) and indoor residual spraying (IRS) in Africa have led to significant reductions in malaria mortality and mobility. However, current first-line interventions are not sufficient to eliminate malaria in most countries. The widespread use of pyrethroid insecticides has resulted in resistant vector populations, and high coverage of LLINs and IRS has led to increased outdoor human feeding behavior and resting behavior. These changes in vector ecology and behaviors have significantly limited the effectiveness of current first-line interventions that target indoor biting and resting mosquitoes. Furthermore, as a result of ecological changes and intervention measures, malaria risk in a locality is dynamic, and the utility of malaria intervention tools may vary as new tools are being approved and introduced and the cost of each tool differs among locations and over time. Such variations in malaria risk, vector ecology, and utility of intervention tools exemplify the need to develop optimal adaptive interventions tailored to local malaria risks, vector ecology and supply chains. The central objective of this application is to design optimal adaptive combinations of vector control interventions to maximize reductions in malaria burden based on local malaria transmission risks, changing vector ecology, and available mix of interventions approved by the Ministry of Health in each target country. The central hypothesis is that an adaptive approach based on local malaria risk and changing vector ecology will lead to significant reductions in malaria incidence and transmission risk. To accomplish this objective, the investigators propose the following three specific aims:

  1. Measure malaria incidence and predict risk using environmental, biological, social, and climatic features with machine learning approaches. Hypothesis: Malaria risk prediction can be improved through the use of machine learning techniques that include environmental, biological, socioeconomic, and climatic features. Approach: Each site will measure malaria incidence, prevalence and social economic factors through community surveys. Classification-based and regression-based approaches will be used to develop malaria risk predictive models, and model performance will be validated. Outcome: This Aim will establish improved malaria risk prediction models and lay an important foundation for developing intervention strategies adaptive to local vector ecology and future malaria risks using reinforced machine learning approaches.
  2. Use a cluster-randomized sequential, multiple assignment randomized trial (SMART) design to develop an optimal adaptive intervention strategy. Hypothesis: Malaria control interventions that are adapted to local malaria risk and vector ecology and are cost effective can be identified using a cluster-randomized SMART design. Approach: Cluster-randomized SMART design will be used in a high transmission areas in Kenya to evaluate the impact of adaptive interventions that involve sequential and combination use of next-generation nets, indoor spraying of non-pyrethroid insecticides, and larval source management for malaria control.
  3. Evaluate the cost-effectiveness and impact of an adaptive intervention approach on secondary endpoints related to malaria risk and transmission. Hypothesis: Intervention strategies adapted to local malaria risk and vector ecology will be more cost-effective in reducing malaria incidence and transmission risk than the currently-used LLIN intervention. Approach: The economic costs of individual interventions or combinations thereof will be assessed from both a provider and societal perspective using standard economic evaluation methodologies. Cost-effectiveness will be measured in terms of cost per person protected. The study will examine changes in drug and insecticide resistance and infection prevalence attributable to the adaptive interventions.

Malaria interventions adapted to rapidly changing malaria risk and vector ecologies are critically needed to improve the effectiveness of malaria control measures. This study will use new techniques, including machine learning and a novel cluster-randomized SMART design, to develop optimal adaptive malaria intervention strategies.

The investigators will use 84 clusters in Kisumu County in Western Kenya to conduct the trial. Since it is a sequential multiple assignment randomized trail, the trial will include several intervention stages. At each stage there will be different interventions. If an intervention is effective (i.e., yields an above threshold reduction in malaria incidence) at Stage 1, the intervention will be continued, otherwise, the intervention will be replaced by another one at Stage 2. The replacement intervention may be decided by different ways, e.g., an known effective intervention or an intervention determined by a machine learning algorithm. Since interventions in some clusters may be continued (i.e., effective) by next stage, other interventions may be replaced by different interventions, the number of interventions arms can vary from stage to stage. This is very different from ordinary cluster randomized trials. In this trial, the investigators planned to start with piperonyl butoxide (PBO) treated long-lasting insecticidal nets (PBO LLIN), indoor residual spraying with Actellic(R) insecticide, and using the routine LLIN intervention as control. Both Actellic IRS and PBO LLIN have been tested to be effective against pyrethroid resistant Anopheles malaria vectors and reduce clinical malaria. Therefore, the initial stage will have three arms, i.e., regular LLIN, PBO LLIN, and regular LLIN plus Actellic IRS. Since the investigators don't know if the effectiveness of these interventions in different clusters, the stage 2 interventions may include up to 7 arms, i.e., some arms may be split into two arms, based on the evaluation at the end of Stage 1 intervention.

The investigators will begin the trial with a two-year smaller scale trial using 36 cluster and randomly assign the three interventions, i.e., regular LLIN, PBO LLIN and regular LLIN plus Actellic IRS, into these 36 cluster, with 12 clusters for each intervention. This pre-trial trial is to determine the optimal way for conducting the full-scale 84 cluster trial, including operational and effectiveness evaluation procedures, as well as cost-effectiveness analysis. The full scale 84 cluster trial will be started by Year 3. The full trial will be started from fresh, i.e., the same three interventions will be randomly assigned to the 84 clusters with 28 clusters for each interventions. Clinical malaria will be monitored using a cohort active case surveillance, parasite prevalence and vector density will be monitored using cross-sectional samplings. The results of these surveillance at the end of Stage 1 trial will be used to evaluate the effectiveness of interventions at each cluster for the Stage 1 interventions. Stage 2 interventions will be determined for each cluster based on the above evaluations, e.g., continue the same intervention or replace the intervention with different ones.

Being tested
Regular long-lasting insecticidal nets, LLIN plus Piperonyl butoxide-treated LLIN, Long-lasting microbial larvicide, Indoor residual spraying with micro-encapsulated pirimiphos-methyl or other insecticides
Keywords
Adaptive intervention, Multiple assignment randomized trial (SMART), Cluster-randomized SMART trial, Optimal intervention strategy, Clinical malaria incidence, Cost-effectiveness

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Regular long-lasting insecticidal netsOther

    Also called LLIN

    Olyset nets: containing 2% permethrin or PermaNet 2.0 containing 1.8 and 1.4 g/kg, respectively, for 75 and 100 denier yarn

  • LLIN plus Piperonyl butoxide-treated LLINOther

    Also called PBO-LLIN

    Olyset Plus: containing 2% permethrin and 1% PBO

  • Long-lasting microbial larvicideOther

    Also called FourStar® 180-day Briquets

    Semi-permanent and permanent habitats will be treated with FourStar® 180-day Briquets using the recommended dosage of 100 ft2 water surface per briquet

  • Indoor residual spraying with micro-encapsulated pirimiphos-methyl or other insecticidesOther

    Also called Actellic 300CS or Kenya government recommended insecticdes

    Each dwelling's interior walls and ceilings will be sprayed with micro-encapsulated pirimiphos-methyl at the recommended dosage of 1g/m² and at the recommended frequency of once a year or twice a year. Other insecticides may be used to replace the Actellic 300 CS depends on Kenya government policy, current policy requires rotating different insecticides annually.

Study groups in NCT04182126
Study groupRoleWhat they receive
Regular long-lasting insecticidal netsPlacebo comparatorAll participants will have LLIN coverage through routine MoH distribution of long-lasting insecticidal nets (LLINs), no other interventions will be applied. Regular LLIN: Olyset nets containing 2% permethrin or PermaNet 2.0 containing 1.8 and 1.4 g/kg, respectively, for 75 and 100 denier yarn.
Receives: Other: Regular long-lasting insecticidal nets
Piperonyl butoxide-treated LLINExperimentalAll participants will received piperonyl butoxide-treated LLINs (PBO-LLINs) at Stage 1 and Stage 2 interventions provided that PBO-LLINs are effective at Stage 1 interventions. Each household will be provided on PBO-LLIN per two people with appropriate eduction. PBO-LLIN: Olyset Plus, containing 2% permethrin and 1% PBO.
Receives: Other: LLIN plus Piperonyl butoxide-treated LLIN
PBO-LLIN plus larval source managementExperimentalAll participants will received piperonyl butoxide-treated LLINs (PBO-LLINs) at Stage 1. However, if Stage 1 intervention is not effective, half of them will randomized to receive PBO-LLINs plus larval source management (LSM) at Stage 2. LSM will be implemented in selected clusters, including chemical methods by larviciding of semi-permanent and permanent habitats, per the National Malaria Strategic Plan of Kenya. The investigators will use the long-lasting microbial larvicides manufactured by Central Life Sciences. Semi-permanent and permanent habitats will be treated with FourStar® 180-day Briquets using the recommended dosage of 100 ft2 water surface per briquet.
Receives: Other: LLIN plus Piperonyl butoxide-treated LLIN; Other: Long-lasting microbial larvicide
PBO-LLIN plus enhanced methodsExperimentalAll participants will received piperonyl butoxide-treated LLINs (PBO-LLINs) at Stage 1, however, Stage 1 intervention is not effective. All participants will received PBO-LLINs plus an enhanced intervention at Stage 2, i.e., annual IRS using Kenya Government recommended insecticides.
Receives: Other: LLIN plus Piperonyl butoxide-treated LLIN
LLIN plus indoor residual sprayingExperimentalAll participants will received regular LLINs plus indoor residual spraying (IRS) (LLIN+IRS) at Stage 1 and Stage 2 interventions provided that LLIN+IRS is effective at Stage 1 interventions. For LLIN+IRS clusters, each dwelling's interior walls and ceilings will be sprayed with micro-encapsulated pirimiphos-methyl (Actellic 300CS) at the recommended dosage of 1g/m² and at the government-recommended frequency. If Kenya government switch the IRS insecticide, the investigators will use the same insecticide as the government recommended.
Receives: Other: Regular long-lasting insecticidal nets; Other: Indoor residual spraying with micro-encapsulated pirimiphos-methyl or other insecticides
LLIN+IRS twice a yearExperimentalAll participants will received regular LLINs plus IRS at Stage 1, provided that LLIN+IRS is not effective. IRS will be increased to twice a year.
Receives: Other: Regular long-lasting insecticidal nets; Other: Long-lasting microbial larvicide; Other: Indoor residual spraying with micro-encapsulated pirimiphos-methyl or other insecticides
LLIN+IRS plus enhanced methodExperimentalAll participants will received regular LLINs plus IRS at Stage 1, provided that LLIN+IRS is not effective. Enhanced method will be added on these clusters at Stage 2 interventions.The enhanced intervention is the regular IRS plus IRS treating animal sheds and other outdoor structures.
Receives: Other: Regular long-lasting insecticidal nets; Other: Indoor residual spraying with micro-encapsulated pirimiphos-methyl or other insecticides

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Annual clinical malaria incidence rate

    To compare clinical malaria incidence rates among different intervention arms

    Measured: Clinical malaria will be monitored for up to 60 months

Secondary outcomes (3)
  1. Malaria infection prevalence

    To compare infection prevalence rates among different intervention arms using microscopic, RDT and molecular diagnostic methods

    Measured: Infection prevalence will be monitored for up to 60 months

  2. Malaria vector density

    To compare malaria vector densities between different intervention arms

    Measured: Vector density will be monitored for up to 60 months

  3. Malaria transmission intensity

    To compare entomological inoculation rates between different intervention arms

    Measured: Entomological inoculation rate will be examined for up to 60 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Dec 2019
  2. Study start1 Dec 2019
  3. Primary completion31 Aug 2024
  4. Study completion31 Aug 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Sequential
Model description
This study will use a longitudinal sequential multiple assignment randomized trial design. It will include multiple stages, at each stage, clusters are assigned to different arms (interventions) using an adaptive strategy. Therefore, number of arms vary from stage to stage.
Masking
Triple blind
Who is masked
Care provider, Investigator, Outcomes assessor
Enrolment
122,872 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04182126
Sponsor's protocol ID
20173512
Status last verified
May 2024
First submitted
25 Nov 2019
Last updated
15 Oct 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Zhou G, Wang X, Lee MC, Machani MG, Kidwell KM, Atieli HE, Kazura JW, Githure JI, Zhong D, Yan G. Adaptive intervention strategies for malaria vector control in western Kenya: a cluster, sequential, multiple-assignment, randomised, open-label trial. Lancet Glob Health. 2026 Jul;14(7):103939. doi: 10.1016/S2214-109X(26)00066-5. Epub 2026 Apr 24.

    PubMed 42044656
  • Zhou G, Lee MC, Atieli HE, Githure JI, Githeko AK, Kazura JW, Yan G. Adaptive interventions for optimizing malaria control: an implementation study protocol for a block-cluster randomized, sequential multiple assignment trial. Trials. 2020 Jul 20;21(1):665. doi: 10.1186/s13063-020-04573-y.

    PubMed 32690063

Questions about this trial

What is this clinical trial studying?

A study testing Regular long-lasting insecticidal nets, LLIN plus Piperonyl butoxide-treated LLIN and Long-lasting microbial larvicide in people with LLIN, PBO LLIN, IRS, Larviciding, run by University of California, Irvine at 2 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United States, Kenya. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Annual clinical malaria incidence rate (time frame: Clinical malaria will be monitored for up to 60 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04182126, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Oct 2024.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in